利拉鲁肽对2型糖尿病合并代谢相关脂肪性肝病患者糖脂代谢及肝功能的影响

Effect of liraglutide on glucose and lipid metabolism and liver function in patients with type 2 diabetes complicated with metabolic fatty liver disease

目的探析利拉鲁肽对2型糖尿病合并代谢相关脂肪性肝病患者糖脂代谢及肝功能的影响。方法纳入2020年1月~2022年6月某院收治的70例2型糖尿病合并代谢相关脂肪性肝病患者作为本次研究对象,按照随机数字表法分为对照组(35例,接受常规保肝、调脂、降糖治疗)和观察组(35例,在常规保肝、调脂、降糖的基础上联合利拉鲁肽治疗)。观察两组患者血糖水平、脂代谢水平、肝功能指标变化情况,统计治疗后患者出现药物不良反应情况。结果治疗前两组患者血糖指标、血脂水平及肝功能指标对比差异无统计学意义(P>0.05);治疗3个月后,两组患者的血糖指标(空腹血糖、餐后2 h血糖及糖化血红蛋白水平)、血脂(低密度脂蛋白、总胆固醇、甘油三酯)水平及肝功能指标(天门冬氨酸氨基转移酶、丙氨酸氨基转移酶及谷氨酰转肽酶)均较治疗前呈明显下降趋势,且观察组下降幅度更为显著,差异均有统计学意义(P<0.05)。两组患者治疗前后及组间的高密度脂蛋白水平比较差异无统计学意义(P>0.05)。观察组不良反应总发生率略高于对照组,但差异无统计学意义(P>0.05)。结论在常规方案的基础上联合利拉鲁肽治疗,可显著改善2型糖尿病合并代谢相关脂肪性肝病患者的糖脂代谢及肝功能水平,且不会产生过多的药物不良反应,安全性较好。

Objective To explore the effect of liraglutide on glucose and lipid metabolism and liver function in patients with type 2 diabetes mellitus complicated with metabolic fatty liver disease.Methods 70 patients with type 2 diabetes complicated with metabolic related fatty liver disease who were admitted to our hospital from January 2020 to June 2022 were included as the study objects.According to the random number table method,they were divided into the control group(35 patients who received routine liver protection,lipid regulation and glucose reduction treatment)and the observation group(35 patients who received liraglutide treatment on the basis of routine liver protection,lipid regulation and glucose reduction).Observe the changes of blood glucose level,lipid metabolism level and liver function indicators of the two groups of patients,and count the adverse drug reactions of patients after treatment.Results There was no significant difference in blood glucose,blood lipid and liver function between the two groups before treatment(P>0.05);After 3 months of treatment,the blood glucose indicators(fasting blood glucose,2h postprandial blood glucose and glycosylated hemoglobin level),blood lipids(low-density lipoprotein,total cholesterol,triglyceride)and liver function indicators(aspartate aminotransferase,alanine aminotransferase,and glutamyltranspeptidase)of the patients in the two groups showed a significant downward trend compared with those before treatment,and the decline in the observation group was more significant,with statistically significant differences(P<0.05).There was no significant difference in high-density lipoprotein levels between the two groups before and after treatment(P>0.05).The total incidence of adverse reactions in the observation group was slightly higher than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Combined with liraglutide on the basis of conventional regimen,it can significantly improve the glucose and lipid metabolism and liver function of patients with metabolic related fatty liver disease in type 2 diabetes,and will not produce too many adverse drug reactions,with good safety.